[Effects of lentinan of peripheral blood mononuclear cell expression of interleukin-2 receptor in patients with chronic hepatitis B in vivo and in vitro].
The effects of lentinan on peripheral blood mononuclear cell (PBMC) expression of IL-2 receptor in patients with chronic hepatitis B in vitro and in vivo were studied. The expression percentage of IL-2 receptor in 44 patients with chronic hepatitis before treatment was 36.74 +/- 7.74, which was lower than healthy subjects, and was 48.92 +/- 3.79 after 2 months treatment of lentinan, which was approximated the normal control. PBMC from 30 patients with chronic hepatitis B were cultured in vitro with or without lentinan. The percentage of expression IL-2 receptor was 12.81 +/- 2.62 without lentinan and was 35.70 +/- 4.87 in the presence of lentinan. The concentration of lentinan stimulating expression of IL-2 receptor was between 0.2 to 200 g.ml-1. The results suggest that lentinan stimulates expression of IL-2 receptor on PBMC, which is associated with the therapeutic effectiveness of lentinan treatment.
Wan
K
K
Department of Infectious Diseases, Third Affiliated Hospital, Hunan Medical University, Changsha.
D000328:Adult; D000368:Aged; D005260:Female; D019694:Hepatitis B, Chronic / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D007912:Lentinan / Q000627:therapeutic use*; D007963:Leukocytes, Mononuclear / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis*
D015375:Receptors, Interleukin-2; D007912:Lentinan